Liver Injury/Regeneration News

Specific mitochondrial biomarker serum levels were greater among patients who did not survive acetaminophen-induced acute liver failure compared with those who survived and recovered, according to new study data.

Can-Fite BioPharma received a US patent for CF102, a drug under development to repair liver cells and function in patients with hepatocellular carcinoma, according to a news release.

Patients with liver injury attributed to ingesting nonbodybuilding herbal and dietary supplements had greater mortality and liver transplantation rates compared with patients taking bodybuilding supplements, according to new study data.

The Acetaminophen Awareness Coalition has issued a safety message to remind consumers to be mindful of the amount of acetaminophen they may ingest when using various cold medicines this flu season, according to a news release.

Researchers at Cedars-Sinai Medical Center have begun testing the safety and efficacy of a bioartificial liver system as a potential treatment for alcohol-related liver disease, according to a news release.

Can-Fite BioPharma received a Japanese patent for CF102, a drug under development to repair liver cells and function in patients with hepatocellular carcinoma, according to a news release.

Among tumor necrosis factor-alpha antagonists, infliximab was most commonly associated with drug-induced liver injury, according to recent study data.

A small percentage of patients with severe acute liver injury enrolled in the Scottish Liver Transplantation Unit tested positive for hepatitis E virus antibodies and RNA, according to data from a new study.

Statins and fibrates included in antiviral treatments among patients with hepatitis C virus were effective in inducing a reduction in viral load, according to new study results.

Race and comorbidities were among important factors that determined death or the need for liver transplantation 6 months after patients were diagnosed with drug-induced liver injury, according to data from a new study.